Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

Published on Oct 1, 2019in Annals of Oncology18.274
· DOI :10.1093/ANNONC/MDZ394.009
Hope S. Rugo107
Estimated H-index: 107
(UCSF: University of California, San Francisco),
Sherene Loi85
Estimated H-index: 85
+ 14 AuthorsLeisha A. Emens54
Estimated H-index: 54
(University of Pittsburgh)
📖 Papers frequently viewed together
88 Citations
370 Citations
594 Citations
Cited By60
#1Katia R. M. Leite (USP: University of São Paulo)H-Index: 31
#2Carlos BarriosH-Index: 28
Last. Fernando Augusto SoaresH-Index: 60
view all 6 authors...
Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. New targeted therapies such as anti-PD-L1 agents are emerging as an option to treat advanced TNBC. A panel of 6 national experts with an active interest in breast cancer convened online. Panel members had either clinical or pathology experience in breast cancer. The expert...
#1Myriam Kossai (French Institute of Health and Medical Research)H-Index: 1
#2Nina Radosevic-Robin (French Institute of Health and Medical Research)H-Index: 22
Last. F. Penault-Llorca (French Institute of Health and Medical Research)H-Index: 1
view all 3 authors...
Therapies that modulate immune response to cancer, such as immune checkpoint inhibitors, began an intense development a few years ago; however, in breast cancer (BC), the results have been relatively disappointing so far. Finding biomarkers for better selection of BC patients for various immunotherapies remains a significant unmet medical need. At present, only tumour tissue programmed death-ligand 1 (PD-L1) and mismatch repair deficiency status are approved as theranostic biomarkers for program...
#1Mieke R Van Bockstal (Cliniques Universitaires Saint-Luc)H-Index: 1
view all 32 authors...
Patients with advanced triple-negative breast cancer (TNBC) benefit from treatment with atezolizumab, provided that the tumor contains ≥1% of PD-L1/SP142-positive immune cells. Numbers of tumor-infiltrating lymphocytes (TILs) vary strongly according to the anatomic localization of TNBC metastases. We investigated inter-pathologist agreement in the assessment of PD-L1/SP142 immunohistochemistry and TILs. Ten pathologists evaluated PD-L1/SP142 expression in a proficiency test comprising 28 primary...
#1Frederick Howard (U of C: University of Chicago)H-Index: 1
#2Dario Villamar (U of C: University of Chicago)
Last. Rita Nanda (U of C: University of Chicago)H-Index: 37
view all 5 authors...
Introduction null Breast cancer has traditionally been viewed as immunogenically 'cold', but two immune checkpoint inhibitors are now approved in combination with chemotherapy for PD-L1 positive advanced triple-negative breast cancer (TNBC), and pembrolizumab was also recently approved for early stage TNBC. As the landscape is rapidly evolving, a comprehensive review of checkpoint inhibitors in breast cancer is needed to aid clinicians in selecting appropriate candidates for therapy, and to high...
#1Paolo Tarantino (IEO: European Institute of Oncology)H-Index: 4
#2Gabriele Antonarelli (IEO: European Institute of Oncology)
Last. Giuseppe Curigliano (IEO: European Institute of Oncology)H-Index: 74
view all 4 authors...
Introduction null Immunotherapy through the blockade of PD1-PDL1 axis has shown to improve outcomes in advanced and early triple negative breast cancer (TNBC). To further enhance immune-stimulation, and ultimately improve patient outcomes, a wide variety of next-generation immunotherapies (NGIO) is being developed for this disease. null Areas covered null In the present article, we discuss the immune landscape of TNBC and recapitulate the rationale and available clinical evidence of NGIO under e...
#1Katsuhiro Yoshikawa (Kansai Medical University)H-Index: 3
#2Mitsuaki Ishida (Kansai Medical University)H-Index: 6
Last. Tomoharu Sugie (Kansai Medical University)H-Index: 9
view all 6 authors...
BACKGROUND Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy is a critical issue. Several assays have been used to evaluate PD-L1 expression, and a few studies comparing PD-L1 expression using various primary antibodies in TNBC tissues have been reported. Howeve...
#1Hina QayoomH-Index: 1
#2Umar MehrajH-Index: 3
Last. Manzoor Ahmad MirH-Index: 5
view all 5 authors...
#1Elizabeth Sakach (Emory University)
#2Ruth M. O’Regan (UR: University of Rochester)
Last. Xiaoxian Li (Emory University)H-Index: 12
view all 4 authors...
Triple negative breast cancer (TNBC) represents 15% to 20% of all primary breast cancers and is the most aggressive subtype of breast cancer. There has been rapid progress in targeted therapy and biomarker development to identify the optimal treatments for TNBC. To update recent developments, this article comprehensively reviews molecular classification and biomarkers of TNBC and targeted therapy developments in immunotherapy, PARP and AKT pathway inhibitors, antibody-drug conjugates and androge...
#1Ioannis ZerdesH-Index: 9
Last. Theodoros FoukakisH-Index: 26
view all 11 authors...
We aimed to assess if the discrepant prognostic information between Programmed Death Ligand 1 (PD-L1) protein versus mRNA expression in early breast cancer (BC) could be attributed to heterogeneity in its expression. PD-L1 protein and mRNA expression in BC tissue microarrays from two clinical patient cohorts were evaluated (105 patients; cohort 1: untreated; cohort 2: neoadjuvant chemotherapy-treated). Immunohistochemistry (IHC) with SP142, SP263 was performed. PD-L1 mRNA was evaluated using bul...
#1Peter Savas (University of Melbourne)H-Index: 24
#2Roberto Salgado (Peter MacCallum Cancer Centre)H-Index: 57
Last. Sherene Loi (University of Melbourne)H-Index: 85
view all 3 authors...
Here we will provide an immune-focussed overview of biomarkers in early and advanced stage breast cancer. It should be noted from the outset that all the biomarkers under discussion here have not been tested in prospective clinical trials to determine their predictive performance. Such trials require very large sample sizes due to the statistical burden of testing an interaction between a treatment and a biomarker, which is compounded by the heterogeneous biology of breast cancer (Polley et al. ...